JWJi Wang

Ji Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ji Wang has a total of 115 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    PRMT1 mediated methylation of YBX1 promotes tumorigenicity of glioblastoma stem cells

    by Ji Wang, Shiquan Shen, Dongshan Zhang, Zongyu Xiao, Tianran Chai, Nan Peng, Xuanzhi Wang, Jingpeng Guo, Honglong Zhou, Liang Chen, et al.

    Glioblastoma (GBM) is the most lethal primary malignant tumor of the adult central nervous system, with glioblastoma stem cells (GSCs) driving tumor progression, treatment resistance, and relapse. Protein arginine methyltransferase 1 (PRMT1) is aberrantly dysregulated in various cancers and is associated with poor prognosis in glioma; However, the critical substrates and molecular mechanisms underlying GSC malignancy remain largely unclear. This study identifies the multifunctional RNA-binding protein Y-box binding protein 1 (YBX1) as a direct substrate of PRMT1. PRMT1 mediates the asymmetric dimethylation of YBX1 at arginine 69 (R69) within its cold-shock domain. Functional experiments, both in vitro and in vivo , confirm that PRMT1 knockdown or chemical inhibition significantly represses GSC proliferation, self-renewal, and tumorigenesis, while overexpression of enzymatically active PRMT1-unlike its catalytically inactive mutant-restores malignant characteristics. Mechanistically, PRMT1 activates the AKT signaling cascade, leading to YBX1 Ser102 phosphorylation and subsequent nuclear import. Furthermore, PRMT1-catalyzed dimethylation of YBX1 at R69 enhances its binding to m5C-modified mRNAs of core cell cycle genes PKMYT1 and CDCA5, stabilizing these transcripts and accelerating GSC cell cycle progression. Consistently, a methylation-deficient YBX1-R69K mutant fails to rescue the proliferative and self-renewal deficits resulting from endogenous YBX1 deletion. A cell-penetrating peptide targeting the YBX1 R69 methylation motif effectively inhibits YBX1 methylation and induces significant anti-tumor effects in GBM xenografts. Clinically, the levels of YBX1-R69 asymmetric dimethylation are positively correlated with PRMT1 abundance, higher tumor grades, and reduced overall survival in patient glioma tissues. In summary, this study reveals an unreported oncogenic PRMT1-YBX1 signaling cascade that sustains GSC malignant features through arginine post-translational modification and mRNA stabilization. Targeting PRMT1-dependent YBX1 arginine methylation may represent a promising therapeutic strategy against GBM.

  • Open Access

    Superficial temporal artery-to-middle cerebral artery side-to-side microvascular anastomosis and cranioplasty in a single-stage procedure: Technical nuances and hemodynamic outcomes

    by Zongyu Xiao, Ji Wang, Liang He, Xiaoci Rong, Likui Shen, Yulun Huang

    Cranioplasty following decompressive craniectomy in patients requiring concurrent cerebral revascularization presents a surgical challenge. While traditional end-to-side bypass may compromise scalp perfusion, a combined single-stage procedure integrating extracranial-to-intracranial (EC-IC) bypass with cranioplasty offers a potential strategy for consolidating treatment, reducing cumulative procedural risks, and optimizing recovery. To assess the feasibility of a single-stage procedure integrating superficial temporal artery (STA)-middle cerebral artery (MCA) side-to-side (S-S) anastomosis with cranioplasty and analyze the postoperative hemodynamic flow distribution. Two patients successfully underwent single-stage STA-MCA S-S microvascular anastomosis with cranioplasty. Good patency of the STA-MCA S-S anastomosis was confirmed by both intraoperative indocyanine green videoangiography (ICG-VA) and postoperative digital subtraction angiography (DSA). On the postoperative DSA, a similar hemodynamic blood flow pattern was observed in both patients, and the proximal STA provided antegrade blood flow to the recipient MCA and the distal STA. No postoperative complications, including cerebral infarction, cerebral hyperperfusion syndrome, or wound healing issues, were observed. A single-stage combined S-S EC-IC anastomosis and cranioplasty procedure offers a viable, safe, and effective surgical strategy for patients requiring EC-IC revascularization and cranioplasty after craniectomy.

  • Open Access

    PRMT3-mediated arginine methylation of YBX1 promotes tumorigenesis in glioblastoma

    by Ji Wang, Shiquan Shen, Dongshan Zhang, Honglong Zhou, Zongyu Xiao, Tianran Chai, Xinzhi Wu, Minghui Zeng, Li Jia, Zheng Li, et al.

    Glioblastoma (GBM) represents one of the most challenging tumor types to treat clinically, characterized by an exceedingly poor patient prognosis. This is primarily attributable to the ambiguous molecular mechanisms that hinder the advancement of targeted therapies. Here, PRMT3 is identified as a key driver of tumorigenesis in GBM. Bioinformatics and clinical data reveal that high expression of PRMT3 in glioma cells is closely correlated with poor patient prognosis. Functional experiments demonstrate that PRMT3 overexpression enhances the proliferative capacity of GBM cells. Mechanistically, PRMT3 interacts with Y-box binding protein 1 (YBX1), and catalyzes the arginine methylation of YBX1 protein at R69 within its cold-shock domain. Subsequently, it was found that methylated YBX1 binds to 5-methylcytosine (m5C)-modified E2F1 mRNA and stabilizes its transcription, significantly promoting the expression of E2F1. The resulting PRMT3-YBX1-E2F1 axis sustains high E2F1 protein levels, activates a proliferation-associated transcriptional program, and is essential for GBM cell proliferation in vitro and in vivo . Meanwhile, the PRMT3 inhibitor SGC707 and the non-methylated YBX1 peptide significantly inhibited the proliferation of GBM cells. Our findings underscore that PRMT3 stabilizes E2F1 transcription through methylation of YBX1 at R69, promoting GBM tumorigenesis, and highlight the PRMT3-YBX1-E2F1 axis as a potential therapeutic target for GBM treatment.

  • Open Access

    Superficial temporal artery-to-middle cerebral artery side-to-side microvascular anastomosis using the in-situ intraluminal suturing technique

    by Zongyu Xiao, Ji Wang, Zhen Bao, Liang He, Xiaochi Rong, Xuetao Li, Haiping Zhu, Zhimin Wang, Yulun Huang

    Background Superficial temporal artery (STA)-middle cerebral artery (MCA) side-to-side microvascular anastomosis can achieve the same clinical effects as traditional STA-MCA end-to-side anastomosis in extracranial-intracranial revascularization surgery, furthermore, STA-MCA side-to-side anastomosis has the lower risk of postoperative cerebral hyperperfusion syndrome (CHS) and the potential to recruit all scalp arteries as the donor sources via self-regulation. Therefore, STA-MCA side-to-side microvascular anastomosis seems to be a revascularization strategy superior to traditional STA-MCA end-to-side anastomosis. In this study, we presented seven cases in which a STA-MCA side-to-side microvascular anastomosis was performed with a 4–5 mm long arteriotomy using the in-situ intraluminal suturing technique. Methods Superficial temporal artery (STA)-middle cerebral artery (MCA) side-to-side anastomosis was performed in seven patients using the in-situ intraluminal suturing technique. Results The diameters of the recipient MCA and the donor STA were approximately 0.94 mm (range 0.8–1.4 mm) and 1.65 mm (range 1.4–2.0 mm), respectively, and the length of the arteriotomy was approximately 4.71 mm (range 4–5 mm). The MCA was temporarily occluded in approximately 25.00 min (range 20–29 min). 100% patency rates of the STA-MCA microvascular anastomosis were achieved in all patients. No obvious CHS was recorded. Intraoperative Indocyanine green videoangiography (ICG-VA) and postoperative digital subtraction angiography (DSA) demonstrated three different blood flow distribution patterns after the STA-MCA side-to-side anastomosis, the donor MCA received not only antegrade blood flow from the proximal preanastomotic STA but also retrograde blood flow from the distal postanastomotic STA in one case; the donor MCA received all the antegrade blood from the proximal STA without retrograde blood flow from the distal STA in two case; whereas, the recipient MCA territories received only partial antegrade blood flow from the proximal preanastomotic STA. Conclusions STA-MCA side-to-side microvascular anastomosis with a 4–5 mm long arteriotomy using the in situ intraluminal suturing technique is a safe and effective revascularization surgery, and the anastomosis can serve as a shunt for blood flow self-regulation.


  • Open Access

    PRMT6 facilitates EZH2 protein stability by inhibiting TRAF6-mediated ubiquitination degradation to promote glioblastoma cell invasion and migration

    by Ji Wang, Shiquan Shen, Jian You, Zhaotao Wang, Yan Li, Yanming Chen, Yonghua Tuo, Danmin Chen, Haoming Yu, Jingbo Zhang, et al.

    Invasion and migration are the key hallmarks of cancer, and aggressive growth is a major factor contributing to treatment failure and poor prognosis in glioblastoma. Protein arginine methyltransferase 6 (PRMT6), as an epigenetic regulator, has been confirmed to promote the malignant proliferation of glioblastoma cells in previous studies. However, the effects of PRMT6 on glioblastoma cell invasion and migration and its underlying mechanisms remain elusive. Here, we report that PRMT6 functions as a driver element for tumor cell invasion and migration in glioblastoma. Bioinformatics analysis and glioma sample detection results demonstrated that PRMT6 is highly expressed in mesenchymal subtype or invasive gliomas, and is significantly negatively correlated with their prognosis. Inhibition of PRMT6 (using PRMT6 shRNA or inhibitor EPZ020411) reduces glioblastoma cell invasion and migration in vitro, whereas overexpression of PRMT6 produces opposite effects. Then, we identified that PRMT6 maintains the protein stability of EZH2 by inhibiting the degradation of EZH2 protein, thereby mediating the invasion and migration of glioblastoma cells. Further mechanistic investigations found that PRMT6 inhibits the transcription of TRAF6 by activating the histone methylation mark (H3R2me2a), and reducing the interaction between TRAF6 and EZH2 to enhance the protein stability of EZH2 in glioblastoma cells. Xenograft tumor assay and HE staining results showed that the expression of PRMT6 could promote the invasion of glioblastoma cells in vivo, the immunohistochemical staining results of mouse brain tissue tumor sections also confirmed the regulatory relationship between PRMT6, TRAF6, and EZH2. Our findings illustrate that PRMT6 suppresses TRAF6 transcription via H3R2me2a to enhance the protein stability of EZH2 to facilitate glioblastoma cell invasion and migration. Blocking the PRMT6-TRAF6-EZH2 axis is a promising strategy for inhibiting glioblastoma cell invasion and migration.


  • Open Access

    PRMT6 facilitates EZH2 protein stability by inhibiting TRAF6-mediated ubiquitination degradation to promote glioblastoma cell invasion and migration

    by Ji Wang, Shiquan Shen, Jian You, Zhaotao Wang, Yan Li, Yanming Chen, Yonghua Tuo, Danmin Chen, Haoming Yu, Jingbo Zhang, et al.

    Invasion and migration are the key hallmarks of cancer, and aggressive growth is a major factor contributing to treatment failure and poor prognosis in glioblastoma. Protein arginine methyltransferase 6 (PRMT6), as an epigenetic regulator, has been confirmed to promote the malignant proliferation of GBM cells in previous studies. However, the effects of PRMT6 on GBM cell invasion and migration and its underlying mechanisms remain elusive. Here, we report that PRMT6 functions as a driver element for tumor cell invasion and migration in glioblastoma. Bioinformatics analysis and glioma sample detection results demonstrated that PRMT6 is highly expressed in mesenchymal subtype or invasive gliomas, and is significantly negatively correlated with their prognosis. Inhibition of PRMT6 (using PRMT6 shRNA or inhibitor EPZ020411) reduces GBM cell invasion and migration in vitro, whereas overexpression of PRMT6 produces opposite effects. Then, we identified that PRMT6 maintains the protein stability of EZH2 by inhibiting the degradation of EZH2 protein, thereby mediating the invasion and migration of GBM cells. Further mechanistic investigations found that PRMT6 inhibits the transcription of TRAF6 by activating the histone methylation mark (H3R2me2a), and reducing the interaction between TRAF6 and EZH2 to enhance the protein stability of EZH2 in GBM cells. Xenograft tumor assay and HE staining results showed that the expression of PRMT6 could promote the invasion of GBM cells in vivo, the immunohistochemical staining results of mouse brain tissue tumor sections also confirmed the regulatory relationship between PRMT6, TRAF6, and EZH2. Our findings illustrate that PRMT6 suppresses TRAF6 transcription via H3R2me2a to enhance the protein stability of EZH2 to facilitate GBM cell invasion and migration. Blocking the PRMT6-TRAF6-EZH2 axis is a promising strategy for inhibiting GBM cell invasion and migration.

  • Open Access

    PRMT1 in human neoplasm: cancer biology and potential therapeutic target

    by Shiquan Shen, Honglong Zhou, Zongyu Xiao, Shaofen Zhan, Yonghua Tuo, Danmin Chen, Xiao Pang, Yezhong Wang, Ji Wang

    Protein arginine methyltransferase 1 (PRMT1), the predominant type I protein arginine methyltransferase, plays a crucial role in normal biological functions by catalyzing the methylation of arginine side chains, specifically monomethylarginine (MMA) and asymmetric dimethylarginine (ADMA), within proteins. Recent investigations have unveiled an association between dysregulated PRMT1 expression and the initiation and progression of tumors, significantly impacting patient prognosis, attributed to PRMT1’s involvement in regulating various facets of tumor cell biology, including DNA damage repair, transcriptional and translational regulation, as well as signal transduction. In this review, we present an overview of recent advancements in PRMT1 research across different tumor types, with a specific focus on its contributions to tumor cell proliferation, metastasis, invasion, and drug resistance. Additionally, we expound on the dynamic functions of PRMT1 during distinct stages of cancer progression, elucidating its unique regulatory mechanisms within the same signaling pathway and distinguishing between its promotive and inhibitory effects. Importantly, we sought to provide a comprehensive summary and analysis of recent research progress on PRMT1 in tumors, contributing to a deeper understanding of its role in tumorigenesis, development, and potential treatment strategies.


  • Open Access

    Supplementary Figure Legend from Pseudogene PTENP1 Functions as a Competing Endogenous RNA to Suppress Clear-Cell Renal Cell Carcinoma Progression

    by Gan Yu, Weimin Yao, Kiranmai Gumireddy, Anping Li, Ji Wang, Wei Xiao, Ke Chen, Haibing Xiao, Heng Li, Kun Tang, et al.

  • Open Access

    Supplementary Figures 1 through 9 from Pseudogene PTENP1 Functions as a Competing Endogenous RNA to Suppress Clear-Cell Renal Cell Carcinoma Progression

    by Gan Yu, Weimin Yao, Kiranmai Gumireddy, Anping Li, Ji Wang, Wei Xiao, Ke Chen, Haibing Xiao, Heng Li, Kun Tang, et al.

    Supplementary Figure 1: PTENP1 and PTEN expression were decreased in human ccRCC samples. Supplementary Figure 2: PTENP1 expression in ACHN and SN12PM6 cells. Supplementary Figure 3: PTENP1 expression activated AKT in ACHN and SN12PM6 cells. Supplementary Figure 4: miR-21 expression in ACHN and SN12PM6 cells. Supplementary Figure 5: PTEN expression in ACHN and SN12PM6 cells. Supplementary Figure 6: 5-10 fold overexpression of PTENP1 increased PTEN expression and suppressed cell proliferation, migration and invasion. Supplementary Figure 7: PTENP1 functions and regulation of PTEN are DICER dependent. Supplementary Figure 8: 5'AZA increased PTENP1 and PTEN expression and suppressed cell proliferation, migration and invasion. Supplementary Figure 9: Cisplatin and gemcitabine treatment increased PTENP1 expression.

  • Open Access

    PRMT6-CDC20 facilitates glioblastoma progression via the degradation of CDKN1B

    by Ji Wang, Zongyu Xiao, Peng Li, Chunwang Wu, Yan Li, Qing Wang, Yanming Chen, Honglong Zhou, Zhi Li, Zhaotao Wang, et al.

    PRMT6, a type I arginine methyltransferase, di-methylates the arginine residues of both histones and non-histones asymmetrically. Increasing evidence indicates that PRMT6 plays a tumor mediator involved in human malignancies. Here, we aim to uncover the essential role and underlying mechanisms of PRMT6 in promoting glioblastoma (GBM) proliferation. Investigation of PRMT6 expression in glioma tissues demonstrated that PRMT6 is overexpressed, and elevated expression of PRMT6 is negatively correlated with poor prognosis in glioma/GBM patients. Silencing PRMT6 inhibited GBM cell proliferation and induced cell cycle arrest at the G0/G1 phase, while overexpressing PRMT6 had opposite results. Further, we found that PRMT6 attenuates the protein stability of CDKN1B by promoting its degradation. Subsequent mechanistic investigations showed that PRMT6 maintains the transcription of CDC20 by activating histone methylation mark (H3R2me2a), and CDC20 interacts with and destabilizes CDKN1B. Rescue experimental results confirmed that PRMT6 promotes the ubiquitinated degradation of CDKN1B and cell proliferation via CDC20. We also verified that the PRMT6 inhibitor (EPZ020411) could attenuate the proliferative effect of GBM cells. Our findings illustrate that PRMT6, an epigenetic mediator, promotes CDC20 transcription via H3R2me2a to mediate the degradation of CDKN1B to facilitate GBM progression. Targeting PRMT6-CDC20-CDKN1B axis might be a promising therapeutic strategy for GBM.